Baxter Healthcare Corporation: Clindamycin Injection Usp In 5% Dextrose, 900 Mg Per
Recall Summary Baxter Healthcare is recalling Clindamycin Injection USP in 5% Dextrose (900 mg per 50 mL) due to manufacturing process deviations that don't meet current Good Manufacturing Practice standards. The affected product was distributed nationwide across all U.S. states, Puerto Rico, and Chile. This is a Class II recall, meaning the product could cause adverse health consequences or death, though that is not certain.
- Recalling firm
- Baxter Healthcare Corporation
- Product
- Clindamycin Injection USP in 5% Dextrose, 900 mg per 50 mL (12 mg/mL) in GALAXY 50 mL Single Dose Container, Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-3814-50.
- Reason
- CGMP Deviations
- Classification
- Class II
- Category
- drug recall
- Country
- United States
- Agency
- U.S. Food and Drug Administration
- Recall date
- 2026-08-06
- Status
- Ongoing
- Areas affected
- AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, ...
- Distribution
- US Nationwide; Puerto Rico; and Chile.
Official recall notice from U.S. Food and Drug Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/bbcc715f-ae62-4108-9b59-387165d9e345